readthroughSign in
Sep 29, 2026Trial update2 fact check notes

ACADIA's ACP-204 open-label extension study in Lewy body dementia psychosis remains recruiting

The Phase 3 extension trial for patients who completed the prior ACP-204-012 study continues enrolling at 32 sites across six countries.

ACADIA Pharmaceuticals' record for its ACP-204 extension study was last updated during the period, with recruitment ongoing.

  • Eligible participants must have completed Visit 6 (EOT) of the antecedent ACP-204-012 study without early discontinuation from that study.1 The trial spans 32 sites in 6 countries: United States, Bulgaria, Czechia, France, Italy, and Serbia.1

Fact check notes

  • Sentence removedThis is a 52-week, Phase 3, open-label extension study of ACP-204 in adults with Lewy body dementia psychosis.copied source wording
  • Sentence removedThe study is listed as recruiting, with an estimated enrollment of 126 participants and a primary completion date estimated for February 2029.a figure with no citation

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.